Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells.

Published on Dec 1, 2013in FEBS Journal4.392
· DOI :10.1111/FEBS.12523
Mirella Meregalli16
Estimated H-index: 16
(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico),
Claire Navarro21
Estimated H-index: 21
(French Institute of Health and Medical Research)
+ 11 AuthorsYvan Torrente48
Estimated H-index: 48
(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Sources
Abstract
The protein dysferlin is abundantly expressed in skeletal and cardiac muscles, where its main function is membrane repair. Mutations in the dysferlin gene are involved in two autosomal recessive muscular dystrophies: Miyoshi myopathy and limb-girdle muscular dystrophy type 2B. Development of effective therapies remains a great challenge. Strategies to repair the dysferlin gene by skipping mutated exons, using antisense oligonucleotides (AONs), may be suitable only for a subset of mutations, while cell and gene therapy can be extended to all mutations. AON-treated blood-derived CD133+ stem cells isolated from patients with Miyoshi myopathy led to partial dysferlin reconstitution in vitro but failed to express dysferlin after intramuscular transplantation into scid/blAJ dysferlin null mice. We thus extended these experiments producing the full-length dysferlin mediated by a lentiviral vector in blood-derived CD133+ stem cells isolated from the same patients. Transplantation of engineered blood-derived CD133+ stem cells into scid/blAJ mice resulted in sufficient dysferlin expression to correct functional deficits in skeletal muscle membrane repair. Our data suggest for the first time that lentivirus-mediated delivery of full-length dysferlin in stem cells isolated from Miyoshi myopathy patients could represent an alternative therapeutic approach for treatment of dysferlinopathies.
📖 Papers frequently viewed together
58 Citations
2016
1 Author (Leticia Fridman)
15 Citations
References59
Newest
#1William E. Grose (OSU: Ohio State University)H-Index: 6
#2K. Reed Clark (OSU: Ohio State University)H-Index: 24
Last. Louise R. Rodino-Klapac (The Research Institute at Nationwide Children's Hospital)H-Index: 33
view all 11 authors...
The dysferlinopathies comprise a group of untreatable muscle disorders including limb girdle muscular dystrophy type 2B, Miyoshi myopathy, distal anterior compartment syndrome, and rigid spine syndrome. As with other forms of muscular dystrophy, adeno-associated virus (AAV) gene transfer is a particularly auspicious treatment strategy, however the size of the DYSF cDNA (6.5 kb) negates packaging into traditional AAV serotypes known to express well in muscle (i.e. rAAV1, 2, 6, 8, 9). Potential ad...
62 CitationsSource
#1Andrea Farini (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 12
#2Clementina Sitzia (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 12
Last. Yvan Torrente (University of Milan)H-Index: 48
view all 11 authors...
Abstract Dysferlin mutations cause muscular dystrophy (dysferlinopathy) characterized by adult onset muscle weakness, high serum creatine kinase levels, attenuation of muscle regeneration and a prominent inflammatory infiltrate. In order to verify the role of lymphocytes and immune cells on this disease, we generated the Scid/A/J transgenic mice and compared these animals with the age-matched A/J mice. The absence of T and B lymphocytes in this animal model of dysferlinopathy resulted in an impr...
20 CitationsSource
#1William Lostal (CNRS: Centre national de la recherche scientifique)H-Index: 9
#1William Lostal (CNRS: Centre national de la recherche scientifique)H-Index: 3
Last. Isabelle Richard (CNRS: Centre national de la recherche scientifique)H-Index: 49
view all 14 authors...
Mutations in the dysferlin gene are the cause of Limb-girdle Muscular Dystrophy type 2B and Miyoshi Myopathy. The dysferlin protein has been implicated in sarcolemmal resealing, leading to the idea that the pathophysiology of dysferlin deficiencies is due to a deficit in membrane repair. Here, we show using two different approaches that fullfiling membrane repair as asseyed by laser wounding assay is not sufficient for alleviating the dysferlin deficient pathology. First, we generated a transgen...
52 CitationsSource
#1Martin Krahn (French Institute of Health and Medical Research)H-Index: 18
#2Nicolas WeinH-Index: 14
Last. Nicolas LévyH-Index: 59
view all 15 authors...
Dysferlinopathies are autosomal recessive, progressive muscle dystrophies caused by mutations in DYSF , leading to a loss or a severe reduction of dysferlin, a key protein in sarcolemmal repair. Currently, no etiological treatment is available for patients affected with dysferlinopathy. As for other muscular dystrophies, gene therapy approaches based on recombinant adeno-associated virus (rAAV) vectors are promising options. However, because dysferlin messenger RNA is far above the natural packa...
63 CitationsSource
#1Jordi Díaz-ManeraH-Index: 30
#2Thierry TouvierH-Index: 14
Last. Giulio Cossu (University of Milan)H-Index: 81
view all 13 authors...
Dysferlin deficiency leads to a peculiar form of muscular dystrophy due to a defect in sarcolemma repair and currently lacks a therapy. We developed a cell therapy protocol with wild-type adult murine mesoangioblasts. These cells differentiate with high efficiency into skeletal muscle in vitro but differ from satellite cells because they do not express Pax7. After intramuscular or intra-arterial administration to SCID/BlAJ mice, a novel model of dysferlinopathy, wild-type mesoangioblasts efficie...
52 CitationsSource
#1William Lostal (CNRS: Centre national de la recherche scientifique)H-Index: 3
#1William Lostal (CNRS: Centre national de la recherche scientifique)H-Index: 9
Last. Isabelle Richard (CNRS: Centre national de la recherche scientifique)H-Index: 49
view all 10 authors...
Deficiency of the dysferlin protein presents as two major clinical phenotypes: limb‐girdle muscular dystrophy type 2B and Miyoshi myopathy. Dysferlin is known to participate in membrane repair, providing a potential hypothesis to the underlying pathophysiology of these diseases. The size of the dysferlin cDNA prevents its direct incorporation into an adeno-associated virus (AAV) vector for therapeutic gene transfer into muscle. To bypass this limitation, we split the dysferlin cDNA at the exon 2...
111 CitationsSource
#1Nicolas Wein (French Institute of Health and Medical Research)H-Index: 14
#2Aurélie Avril (UPMC: Pierre-and-Marie-Curie University)H-Index: 2
Last. Nicolas Lévy (French Institute of Health and Medical Research)H-Index: 59
view all 12 authors...
Mutations in DYSF encoding dysferlin cause primary dysferlinopathies, autosomal recessive diseases that mainly present clinically as Limb Girdle Muscular Dystrophy type 2B and Miyoshi myopathy. More than 350 different sequence variants have been reported in DYSF. Like dystrophin, the size of the dysferlin mRNA is above the limited packaging size of AAV vectors. Alternative strategies to AAV gene transfer in muscle cells must then be addressed for patients. A gene therapy approach for Duchenne mu...
80 CitationsSource
#1Douglas P. Millay (Cincinnati Children's Hospital Medical Center)H-Index: 22
#2Marjorie Maillet (Cincinnati Children's Hospital Medical Center)H-Index: 22
Last. Jeffery D. Molkentin (Cincinnati Children's Hospital Medical Center)H-Index: 144
view all 7 authors...
Mutations in the gene DYSF, which codes for the protein dysferlin, underlie Miyoshi myopathy and limb-girdle muscular dystrophy 2B in humans and produce a slowly progressing skeletal muscle degenerative disease in mice. Dysferlin is a Ca2+-sensing, regulatory protein that is involved in membrane repair after injury. To assess the function of dysferlin in healthy and dystrophic skeletal muscle, we generated skeletal muscle–specific transgenic mice with threefold overexpression of this protein. Th...
50 CitationsSource
#1Martin KrahnH-Index: 18
#2Ana BorgesH-Index: 2
Last. Nicolas LévyH-Index: 59
view all 9 authors...
We report for the first time the characterization of disease-causing exonic rearrangements in the large-sized gene encoding dysferlin. A newly developed kit for multiplex ligation-dependent probe amplification analysis of the dysferlin gene was used for a total of 12 samples from patients with suspected diagnosis of primary dysferlinopathy. This analysis and subsequent genomic quantitative real-time PCR evidenced exonic rearrangements in five patients, including four different exonic deletions a...
15 CitationsSource
#1François Olivier Desmet (University of Montpellier)H-Index: 1
#2Dalil Hamroun (University of Montpellier)H-Index: 22
Last. Christophe Béroud (University of Montpellier)H-Index: 65
view all 6 authors...
Thousands of mutations are identified yearly. Although many directly affect protein expression, an increasing proportion of mutations is now believed to influence mRNA splicing. They mostly affect existing splice sites, but synonymous, non-synonymous or nonsense mutations can also create or disrupt splice sites or auxiliary cis-splicing sequences. To facilitate the analysis of the different mutations, we designed Human Splicing Finder (HSF), a tool to predict the effects of mutations on splicing...
1,836 CitationsSource
Cited By10
Newest
#1Stefano Biressi (University of Trento)H-Index: 15
#2Antonio Filareto (Boehringer Ingelheim)H-Index: 11
Last. Thomas A. Rando (Stanford University)H-Index: 88
view all 3 authors...
Muscular dystrophies are a heterogeneous group of genetic diseases, characterized by progressive degeneration of skeletal and cardiac muscle. Despite the intense investigation of different therapeutic options, a definitive treatment has not been yet developed for this debilitating class of pathologies. Cell-based therapies in muscular dystrophies have been pursued experimentally for the last three decades. Several cell types with different characteristics and tissues of origin, including myogeni...
6 CitationsSource
#1William Lostal (Université Paris-Saclay)H-Index: 1
#1William Lostal (French Institute of Health and Medical Research)H-Index: 9
Last. Isabelle Richard (French Institute of Health and Medical Research)H-Index: 22
view all 2 authors...
Dysferlin deficiencies are responsible for muscular dystrophies with different presentations with the most frequent being limb-girdle muscular dystrophy type 2B and Miyoshi myopathy. The dysferlin (DYSF) gene is expressed through a 6.2 kb coding sequence, a size that impedes classical gene transfer approach using adeno-associated vectors (AAVs). There is no treatment for dysferlin deficiencies, but in the last decade, a large spectrum of strategies has been evaluated in different setups. In this...
Source
#1Florian Barthélémy (UCLA: University of California, Los Angeles)H-Index: 8
#2Nicolas Wein (OSU: Ohio State University)H-Index: 14
Abstract Dystrophinopathies are diseases caused by mutations in the Duchenne Muscular Dystrophy gene (DMD) encoding the dystrophin protein. Depending on the type of mutation, patients develop either the severe DMD or the milder Becker Muscular Dystrophy. Although substantial effort was made, the pathophysiology and variation in disease severity are still poorly understood. During the last two decades, relentless efforts were made to develop therapeutic strategies. Among these, gene therapy and c...
24 CitationsSource
#1Corrado AngeliniH-Index: 122
#2Marina Fanin (UNIPD: University of Padua)H-Index: 47
ABSTRACTIntroduction: Limb Girdle Muscular Dystrophies (LGMD) are a clinically heterogeneous group of disorders presenting with a spectrum of disease severity ranging from severe childhood onset muscular dystrophy to adult-onset dystrophy. LGMDs include both dominant and recessive forms.Areas covered: The clinical phenotypes and diagnostic features of LGMD and specific features for each disease have been presented. An updated list of molecularly defined LGMD is provided. The instrumental, muscle...
6 CitationsSource
#1Helena Escobar (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 4
#2Verena Schöwel (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 5
Last. Zsuzsanna Izsvák (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 60
view all 5 authors...
Dysferlin-deficient muscular dystrophy is a progressive disease characterized by muscle weakness and wasting for which there is no treatment. It is caused by mutations in DYSF, a large, multiexonic gene that forms a coding sequence of 6.2 kb. Sleeping Beauty (SB) transposon is a nonviral gene transfer vector, already used in clinical trials. The hyperactive SB system consists of a transposon DNA sequence and a transposase protein, SB100X, that can integrate DNA over 10 kb into the target genome....
21 CitationsSource
#1A MurphyH-Index: 10
#2Volker Straub (Newcastle University)H-Index: 85
Over sixty years ago John Walton and Frederick Nattrass defined limb girdle muscular dystrophy (LGMD) as a separate entity from the X-linked dystrophinopathies such as Duchenne and Becker muscular dystrophies. LGMD is a highly heterogeneous group of very rare neuromuscular disorders whose common factor is their autosomal inheritance. Sixty years later, with the development of increasingly advanced molecular genetic investigations, a more precise classification and understanding of the pathogenes...
34 CitationsSource
#1Sara BenedettiH-Index: 13
#2Giulio CossuH-Index: 81
Last. Francesco Saverio TedescoH-Index: 21
view all 3 authors...
As with the previous edition, this book covers all aspects of gene and cell therapies from bench to bedside in chapters contributed by authors worldwide.
1 Citations
Skeletal muscle tissue engineering is a relatively new field exploiting knowledge of histology, cell biology, medicine, chemistry, and engineering to regenerate, reconstruct, and replace damaged or lost muscles. The detailed picture of the muscle histophysiology, the characteristic organization of the muscular tissue, and the influence of specific location (cell niche) on muscle stem cell behavior explain the rationale of limited results obtained so far to mimic this complex architectural organi...
Source
Over sixty years ago John Walton and Frederick Nattrass defined limb girdle muscular dystrophy (LGMD) as a separate entity from the X-linked dystrophinopathies such as Duchenne and Becker muscular dystrophies. LGMD is a highly heterogeneous group of very rare neuromuscular disorders whose common factor is their autosomal inheritance. Sixty years later, with the development of increasingly advanced molecular genetic investigations, a more precise classification and understanding of the pathogenes...
#1Alba Judith Mateos-Aierdi (ISCIII: Carlos III Health Institute)H-Index: 2
#2Ana Aiastui (ISCIII: Carlos III Health Institute)H-Index: 11
Last. Adolfo López de Munain (UPV/EHU: University of the Basque Country)H-Index: 46
view all 4 authors...
Limb-girdle muscular dystrophies (LGMDs) comprise a heterogeneous group of genetically determined disorders in which degeneration of the skeletal muscle is prominent. As no efficient pharmacological therapies exist that are able to reverse the course of these diseases, alternative regenerative therapies based on cell transfer or gene transfer approaches have been developed. These latter therapies will be the topic of this mini-review. To date, recombinant adeno-associated viral vectors have been...
1 CitationsSource